NOS2 and neoplasm: To activate the tumor immune microenvironment, we utilized an immunomodulatory treatment previously developed by our group [20] combining weekly CTX injections with continuous delivery of the iNOS inhibitor, L-NIL, in drinking water (Additional file 1: Figure S1A).